Join us for an in-depth webinar showcasing the power of ultra-sensitive cytokine detection using Quanterix’s Simoa® platform. Jingwen Tan, Director of Biomarker Services at Frontage Laboratories, will walk through a study validating the Simoa IL-17A assay in human serum, demonstrating exceptional sensitivity, precision, and robustness. You will gain insight into the complete validation workflow and key performance metrics essential for therapeutic monitoring. Wes Straub, VP, Product Management, will also introduce the Simoa Cytokine Advantage PLUS product line and its versatility across multiple therapeutic areas. This session offers practical guidance on implementing high-sensitivity multiplexing into your research or development pipeline. Learn how the Simoa platform addresses limitations of traditional immunoassays and advances precision biomarker discovery.

What You’ll Learn:

• How Frontage Labs validated an ultra-sensitive IL-17A assay using Simoa for serum samples.
• Key performance metrics including sensitivity, reproducibility, and matrix effects.
• Applications of Simoa® cytokine assays in immuno-oncology, autoimmunity, and infectious diseases.
• How Simoa compares with other cytokine multiplex platforms in sensitivity and scalability.
• How to incorporate Simoa assays into CRO, pharma, and academic biomarker pipelines.

Speaker Info:

Jingwen Tan, PhD
Director of Biomarker Services
Frontage Laboratories, Inc.

Dr. Jingwen Tan is the Director of Biomarker Services at Frontage Laboratories Inc., where she leads biomarker and bioanalytical innovation. With over a decade of experience in chemical engineering, biomaterials, and translational neuroscience, she brings a multidisciplinary perspective to bioanalytical assay development. Notably, Dr. Tan specializes in ultra-sensitive assay validation that helps to detect biomarkers at low levels; critical for advancing drug development and clinical research. In this webinar, Dr. Tan will walk us through what makes ultra-high sensitive bioanalytical assays so powerful, how they’re developed and validated, and how the validated assay can support laboratory and clinical research.

Wesley Straub, PhD
VP, Product Management
Quanterix

Wesley Straub obtained his B.S. in Chemistry magna cum laude from Boston University and a Ph.D. from the University of California San Francisco. After working on the production, purification and characterization of several biosimilars, recombinant blood factors and novel biotherapeutics, he entered the life science technology with Forte Bio. He has contributed to the development and launch of over 25 hardware, software and reagent products across BLI, capillary sequencing, qPCR and Simoa technologies.